Compare ANNX & MBWM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANNX | MBWM |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.7M | 928.7M |
| IPO Year | 2020 | 1997 |
| Metric | ANNX | MBWM |
|---|---|---|
| Price | $4.98 | $54.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $16.50 | ★ $55.67 |
| AVG Volume (30 Days) | ★ 2.6M | 121.3K |
| Earning Date | 05-11-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | N/A | ★ 10.95 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.28 |
| Revenue Next Year | $16,320.74 | $4.67 |
| P/E Ratio | ★ N/A | $40.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.85 | $42.69 |
| 52 Week High | $7.18 | $55.77 |
| Indicator | ANNX | MBWM |
|---|---|---|
| Relative Strength Index (RSI) | 44.46 | 53.98 |
| Support Level | $4.80 | $50.02 |
| Resistance Level | $5.07 | $54.00 |
| Average True Range (ATR) | 0.36 | 1.46 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 32.19 | 61.10 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.